Nov. 16 at 12:10 PM
$CAPR
something to gnaw on.
Eteplirsen (Exondys 51), approved by the FDA on Sept 19, 2016, ~13% of DMD amenable to exon 51 skipping. Etep generated just
$5.4M net revenue for rest of 2016, but hit
$154M 2017.
SRPT traded at ~
$28 pre approval, surged to
$63 on approval but dipped back to ~
$30 due to payer concerns and pricing debates. SRPT closed at ~
$130 on Etep sales at the end of 2017. Just 15 months after approval.
CAPR hit >
$23 based on news of rolling BLA in 2024. Today at
$5.5 pre Topline is a bargain!
Upon approval, 100 patients from OLE turns to payers not including those in queue, NS Pharma prospects to receive the drug. D patient treatment cost based on SRPTs exon skippers, ~
$750K per year.
Linda estimated patients 500 initially, ramp up to address 15K US DMD prevalence, ~ or >half non amb.
Bottom line those expecting further volatility downside will be disappointed! This is KMart blue light special bargain price reved up to moonshot on Topline results.
